Kapil Arya
Neurology · Little Rock, ARNPI 1538319884
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Genentech USA, Inc. at 55.9% of the total.
Across 34 payments — averaging $474.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$9K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$4K
- Genentech, Inc.$3K
- Neuropace, Inc.$151
- J2 Bio-pharma LLC$100
- Novartis$63
- plus $98 from 3 others
Across 78 payments — averaging $4979.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$183K
- Genentech, Inc.$112K
- Novartis$48K
- Biomarin Pharmaceutical Inc.$25K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$20K
What the payments were for
- Consulting fees$8,58553%
- Speaking & faculty fees$3,00119%
- Travel & lodging$1,58710%
- Food & beverage$2,16113%
- Education$6954%
- Gifts$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 8 | $9,018 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 6 | $3,729 |
| Genentech, Inc. | 14 | $2,971 |
| Neuropace, Inc. | 1 | $151 |
| J2 Bio-pharma LLC | 1 | $100 |
| Novartis | 1 | $63 |
| Biomarin Pharmaceutical Inc. | 1 | $38 |
| Biogen | 1 | $35 |
| Sarepta Therapeutics, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVRYSDI$10,659
- ZOLGENSMA$3,483
- RNS Neurostimulator Kit$151
How this compares
$16,129 in reported general payments places this provider in the 80th percentile of 93 neurology providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 12 | $1,054 |
Paid to pharmacies, not to this prescriber.
Other neurology in Little Rock
- Shitiz SriwastavaLittle Rock$59K
- Elizabeth SullivanLittle Rock$33K
- Robert SilzerLittle Rock$14K
- Bradley BoopLittle Rock$13K
- Duane BirkyLittle Rock$12K
- Abdel Rahman SalehLittle Rock$10K
- John IronsideLittle Rock$10K
- Christopher WrightLittle Rock$9K
- Srilatha ThadurLittle Rock$7K
- Mitchell KaufmanLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.